18889881171
Kalkine 0
countryflagUS

Annovis Bio Inc

Healthcare US ANVS

2.85USD
-0.09(3.06%)

Last update at 2025-06-13T16:55:00Z

Day Range

2.843.08
LowHigh

52 Week Range

5.4223.89
LowHigh

Fundamentals

  • Previous Close 2.94
  • Market Cap157.53M
  • Volume251214
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-4.84

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -25.32857M -14.48713M -5.46205M -0.99098M -0.71387M
Minority interest - - - - -
Net income -25.14586M -14.43704M -4.25737M -0.29684M -0.71387M
Selling general administrative 9.00M 6.06M 3.59M 0.83M 0.60M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -14.53722M -6.64022M -1.60562M -0.71407M
Ebitda -25.51128M -14.50047M -5.45627M -0.79105M -0.71394M
Depreciation and amortization - 0.04M 1.18M 0.81M 0.00013M
Non operating income net other - 0.04M 1.13M - -
Operating income -25.51128M -14.53722M -6.64022M -1.60562M -0.71394M
Other operating expenses 25.51M 14.50M 5.48M 0.87M 0.71M
Interest expense -0.18271M 0.01M 47.23M -40.93300M 0.00007M
Tax provision - - - - -
Interest income 0.18M 0.01M - - -
Net interest income 0.18M 0.01M 0.05M -0.04093M 0.00007M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.18271M -0.05009M -1.20467M -0.69414M -0.00013M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 25.51M 14.50M 5.48M 0.87M 0.71M
Cost of revenue - - - - -
Total other income expense net 0.18M 0.05M 1.18M 0.61M 0.00007M
Discontinued operations - - - - -
Net income from continuing ops -25.32857M -14.48713M -5.46205M -0.99098M -0.71387M
Net income applicable to common shares - -14.48713M -5.46205M -0.99098M -0.71387M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 36.02M 46.00M 8.12M 1.12M 0.05M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 7644.38M 315.46M 44.68M 745.65M 0.02M
Total liab 7.70M 1.51M 0.58M 9.69M 7.64M
Total stockholder equity 28.32M 44.49M 7.54M -8.57640M -7.59390M
Deferred long term liab - - - 0.37M -
Other current liab 3.74M 0.82M 0.24M 0.78M 0.50M
Common stock 0.00082M 0.00081M 0.00069M 0.00003M 0.00003M
Capital stock 0.00082M 0.00081M 0.00069M 0.00003M 0.00003M
Retained earnings -54.05477M -28.72621M -14.23907M -8.77703M -7.78605M
Other liab - - - 0.11M -
Good will - - - - -
Other assets - - - 0.37M -
Cash 28.38M 45.69M 8.07M 0.00186M 0.04M
Cash and equivalents - - - - -
Total current liabilities 7.70M 1.51M 0.58M 2.01M 0.57M
Current deferred revenue - - - - -
Net debt -28.37769M -45.68601M -8.07466M 0.50M -0.03531M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - 0.50M -
Other stockholder equity 82.38M 73.22M 21.78M 0.20M 0.19M
Property plant equipment - - - - -
Total current assets 36.02M 46.00M 8.12M 0.75M 0.05M
Long term investments - - - - -
Net tangible assets - 44.49M 7.54M -8.57640M -7.59390M
Short term investments - - - - -
Net receivables - - - 0.74M -
Long term debt - - - 0.50M -
Inventory - - - -745.64342M -
Accounts payable 3.96M 0.69M 0.34M 1.23M 0.07M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - 0.00081M 0.00069M 0.00003M 0.00003M
Preferred stock total equity - - - - -
Retained earnings total equity - -28.72621M -14.23907M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.37M 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.00000M 0.00000M 0.37M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - 0.50M -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - -
Change to liabilities - 0.93M -1.10169M 0.97M -0.00268M
Total cashflows from investing activities - - - - -
Net borrowings - - - 0.53M 0.53M
Total cash from financing activities 0.00461M 46.74M 12.04M 0.44M 0.25M
Change to operating activities - 0.31M 0.29M -0.54756M 0.08M
Net income -25.32857M -14.48713M -5.46205M -0.99098M -0.71387M
Change in cash -17.30832M 37.61M 8.07M -0.03345M -0.31216M
Begin period cash flow 45.69M 8.07M 0.00186M 0.04M 0.35M
End period cash flow 28.38M 45.69M 8.07M 0.00186M 0.04M
Total cash from operating activities -17.31293M -9.13216M -3.97082M -0.47654M -0.55861M
Issuance of capital stock 0.00000M 46.65M 12.03M 0.00000M 0.25M
Depreciation - - 0.13M 1.19M -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - 0.74M - -
Sale purchase of stock - 46.74M 12.04M - 0.25M
Other cashflows from financing activities 0.00461M 0.10M 0.00922M 0.44M 0.24M
Change to netincome - 4.70M 1.89M 0.09M 0.08M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - -0.27079M 0.70M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - 37.61M 8.07M - -
Change in working capital -1.13689M 0.66M -0.40071M 0.42M 0.07M
Stock based compensation 9.15M 4.70M 1.86M 0.00848M 0.08M
Other non cash items - 14472.64M 0.03M 0.08M 0.46M
Free cash flow -17.31293M -9.13216M -3.97082M -0.47654M -0.55861M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ANVS
Annovis Bio Inc		 -0.09 3.06% 2.85 - - - 16.57 -2.4524
NVO
Novo Nordisk A/S		 -0.56 0.69% 80.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.41 0.51% 80.59 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.29 0.28% 458.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.82 0.54% 524.66 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Annovis Bio Inc

1055 Westlakes Drive, Berwyn, PA, United States, 19312

Key Executives

Name Title Year Born
Dr. Maria L. Maccecchini Ph.D. Founder, CEO, Pres & Exec. Director 1951
Mr. Henry Hagopian III, M.B.A. Chief Financial Officer 1968
Dr. Cheng Fang Ph.D. Sr. VP of R&D NA
Ms. Eve M. Damiano M.S., RAC Sr. VP of Regulatory Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.